A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate or darolutamide

Trial Details

NCT ID
NCT06844383
Phase
PHASE2
Sponsor
Prostate Cancer Clinical Trials Consortium
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Talazoparib with enzalutamide
  • Talazoparib
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • La Jolla, California, United States|32.84727,-117.2742
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Minneapolis, Minnesota, United States|44.97997,-93.26384
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Willing and able to provide, or have a legally authorized representative provide, written informed consent and privacy authorization for the releas…
  • NOTE: Privacy authorization may be either included in the informed consent or obtained separately.
  • Participants ≥ 18 years of age.
  • Are willing to be randomized into either study arm and adhere to the study protocol.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →